

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
M. Kröz <i>et al.</i>)	Art Unit: 1646
)	
Application No. 10/584,438)	Examiner: Dong Jiang
)	
Filing Date: January 29, 2008		
(International Filing Date: 12/03/2004))	Confirmation No. 2609
)	
For: INTERLEUKIN-11 FUSION PROTEINS)	

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BALLARD SPAHR ANDREWS &
INGERSOLL, LLP

Customer Number 23859

Sir:


In response to the Requirement for Restriction dated February 6, 2009, Applicants elect to prosecute the claims of Group III, that is, claims 25-29, 32 and 33 drawn to a method of treatment with an albumin-fused IL-11. With regard to this group, Applicants further elect to prosecute species (1) drawn to minimizing a side effect associated with IL-11 treatment. Claims 25, 26, 28, 29 and 33 are readable on the elected species. Applicants confirm their right to file divisional applications that include the non-elected claims.

A favorable action on the merits is requested respectfully.


ATTORNEY DOCKET NO. 16238.0002U1
APPLICATION NO. 10/584,438

Respectfully submitted,

BALLARD SPAHR ANDREWS &
INGERSOLL, LLP


Marc S. Segal
Registration No. 40,163

BALLARD SPAHR ANDREWS &
INGERSOLL, LLP
Customer Number 23859
(215) 864-8843
(678) 420-9301 (fax)

CERTIFICATE OF ELECTRONIC TRANSMISSION UNDER 37 C.F.R. § 1.8			
I hereby certify that this correspondence, including any items indicated as attached or included, is being transmitted via electronic transmission via EFS-Web on the date indicated below.			
Name of Person Mailing (Print/Type)	Marc S. Segal		
Signature		Date	3/5/2009